New CONFORM Trial Digital Tool

INTRODUCING THE

NEW CONFORMTRIAL.COM

Share this new site with your patients who may be appropriate candidates for the CONFORM Trial.

A new site to help inform and educate prospective patients seeking an alternative to long-term blood thinners for stroke risk reduction in non-valvular atrial fibrillation.

VISIT THE NEW CONFORMTRIAL.COM

CONFORM Trial.com offers study information in one digital location. This new site is intended to provide clear, patient-friendly information about the trial, including eligibility criteria, how to participate, and the benefits of participating in a clinical study.

Physician & Research Coordinator Tools

Access the CONFORM App and the Research Coordinator Hub anytime, anywhere. These tools offer quick and easy access to essential information about the CONFORM Trial—keeping you informed and connected on the go.

The CONFORM Trial App

A mobile solution to access information about the study at your fingertips.

View enrollment activities and more.

Access resources
Find helpful videos and articles
View other Implanting physicians
Updates on news & events

Download or Access Here

CONFORM Trial Research HUB

Your digital resource center for all your CONFORM Study Tools, guides, and quick links.

Get the latest updates and access to:

Protocol revisions
Study startup documentation
Request patient materials
Download templates

Visit The Site Here

Have suggestions or questions about this newsletter?

Drop us a note at info@conformalmedical.com.

CAUTION: Investigational Device

The CLAAS System is limited by Federal (or United States) law to investigational use.

© 2025 Conformal Medical, Inc.
Conformal, CLAAS, and The Shape of Stroke Prevention are registered trademarks and AcuFORM is a trademark of Conformal Medical, Inc

conformalmedical.com | contact us

DISCLAIMER: The information contained in this email (including any file attachments transmitted with it) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorised review, use, alteration, disclosure, copying or distribution is prohibited. If you have received this email in error, please notify the sender by return email and destroy all copies of the original message. Any confidentiality or privilege is not waived or lost by any mistaken delivery of this email.